{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T06:40:19Z","timestamp":1791268819862,"version":"4.1.0"},"reference-count":189,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2012,7,1]],"date-time":"2012-07-01T00:00:00Z","timestamp":1341100800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmacology & Therapeutics"],"published-print":{"date-parts":[[2012,7]]},"DOI":"10.1016\/j.pharmthera.2012.04.001","type":"journal-article","created":{"date-parts":[[2012,4,6]],"date-time":"2012-04-06T12:27:23Z","timestamp":1333715243000},"page":"78-93","source":"Crossref","is-referenced-by-count":20,"title":["Prevention of aortic valve stenosis: A realistic therapeutic target?"],"prefix":"10.1016","volume":"135","author":[{"given":"D.T.","family":"Ngo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.L.","family":"Sverdlov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.D.","family":"Horowitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.pharmthera.2012.04.001_bb0005","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1161\/CIRCULATIONAHA.109.934059","article-title":"Metabolic modulator perhexiline corrects energy deficiency and improves exercise capacity in symptomatic hypertrophic cardiomyopathy","volume":"122","author":"Abozguia","year":"2010","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2012.04.001_bb0010","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1001\/jama.285.19.2486","article-title":"Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults","volume":"285","author":"Adult Treatment Panel III","year":"2001","journal-title":"JAMA"},{"key":"10.1016\/j.pharmthera.2012.04.001_bb0015","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1136\/heart.86.4.381","article-title":"Treatment decision in asymptomatic aortic valve stenosis: role of exercise testing","volume":"86","author":"Amato","year":"2001","journal-title":"Heart"},{"key":"10.1016\/j.pharmthera.2012.04.001_bb0020","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1016\/j.jacc.2006.11.043","article-title":"Angiotensin receptor-1 blocker inhibits atherosclerotic changes and endothelial disruption of the aortic valve in hypercholesterolemic rabbits","volume":"49","author":"Arishiro","year":"2007","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pharmthera.2012.04.001_bb0025","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/S0002-9149(01)01821-5","article-title":"Association of coronary risk factors and use of statins with progression of mild valvular aortic valve stenosis in older persons","volume":"88","author":"Aronow","year":"2001","journal-title":"Am J Cardiol"},{"issue":"599\u2013600","key":"10.1016\/j.pharmthera.2012.04.001_bb0030","first-page":"A598","article-title":"Comparison of frequency of new coronary events in older subjects with and without valvular aortic sclerosis","volume":"83","author":"Aronow","year":"1999","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.pharmthera.2012.04.001_bb0035","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1016\/S0002-9149(99)00496-8","article-title":"Factors leading to progression of valvular aortic valve stenosis","volume":"84","author":"Bahler","year":"1999","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.pharmthera.2012.04.001_bb0040","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/j.athoracsur.2009.10.033","article-title":"Severe aortic valve stenosis in a veteran population: treatment considerations and survival","volume":"89","author":"Bakaeen","year":"2010","journal-title":"Ann Thorac Surg"},{"key":"10.1016\/j.pharmthera.2012.04.001_bb0045","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1016\/S0735-1097(02)02496-8","article-title":"Association of cholesterol levels, hydroxymethylglutaryl coenzyme-A reductase inhibitor treatment, and progression of aortic valve stenosis in the community","volume":"40","author":"Bellamy","year":"2002","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pharmthera.2012.04.001_bb0050","doi-asserted-by":"crossref","first-page":"28514","DOI":"10.1074\/jbc.274.40.28514","article-title":"Regulation of osteogenesis by fetuin","volume":"274","author":"Binkert","year":"1999","journal-title":"J Biol Chem"},{"key":"10.1016\/j.pharmthera.2012.04.001_bb0055","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1016\/S0008-6363(03)00500-5","article-title":"The emerging role of asymmetric dimethylarginine as a novel cardiovascular risk factor","volume":"59","author":"Boger","year":"2003","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.pharmthera.2012.04.001_bb0060","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1161\/01.CIR.96.4.1282","article-title":"Dietary L-arginine reduces the progression of atherosclerosis in cholesterol-fed rabbits: comparison with lovastatin","volume":"96","author":"Boger","year":"1997","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2012.04.001_bb0065","series-title":"Primary Cardiology","author":"Braunwald","year":"2003"},{"key":"10.1016\/j.pharmthera.2012.04.001_bb0070","doi-asserted-by":"crossref","first-page":"2229","DOI":"10.1016\/j.jacc.2005.12.073","article-title":"Metabolic syndrome negatively influences disease progression and prognosis in aortic valve stenosis","volume":"47","author":"Briand","year":"2006","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pharmthera.2012.04.001_bb0075","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.jtcvs.2008.08.015","article-title":"Isolated aortic valve replacement in North America comprising 108,687 patients in 10 years: changes in risks, valve types, and outcomes in the Society of Thoracic Surgeons National Database","volume":"137","author":"Brown","year":"2009","journal-title":"J Thorac Cardiovasc Surg"},{"key":"10.1016\/j.pharmthera.2012.04.001_bb0080","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1101\/gad.12.9.1260","article-title":"osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification","volume":"12","author":"Bucay","year":"1998","journal-title":"Genes Dev"},{"key":"10.1016\/j.pharmthera.2012.04.001_bb0085","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.1161\/01.CIR.0000015507.29953.38","article-title":"Elevated C-reactive protein values and atherosclerosis in sudden coronary death: association with different pathologies","volume":"105","author":"Burke","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2012.04.001_bb0090","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1161\/01.ATV.0000196624.70507.0d","article-title":"Transcriptional profiles of valvular and vascular endothelial cells reveal phenotypic differences: influence of shear stress","volume":"26","author":"Butcher","year":"2006","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.pharmthera.2012.04.001_bb0095","doi-asserted-by":"crossref","first-page":"96","DOI":"10.2459\/JCM.0b013e32833cdcea","article-title":"Association between plasma asymmetrical dimethylarginine activity and severity of aortic valve stenosis","volume":"12","author":"Cagirci","year":"2011","journal-title":"J Cardiovasc Med (Hagerstown)"},{"key":"10.1016\/j.pharmthera.2012.04.001_bb0100","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1016\/j.jacc.2006.02.040","article-title":"Human degenerative valve disease is associated with up-regulation of low-density lipoprotein receptor-related protein 5 receptor-mediated bone formation","volume":"47","author":"Caira","year":"2006","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pharmthera.2012.04.001_bb0105","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/S0140-6736(09)60211-7","article-title":"Aortic valve stenosis","volume":"373","author":"Carabello","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.pharmthera.2012.04.001_bb0110","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1016\/0140-6736(92)93147-F","article-title":"Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis","volume":"340","author":"Celermajer","year":"1992","journal-title":"Lancet"},{"key":"10.1016\/j.pharmthera.2012.04.001_bb0115","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1161\/CIRCULATIONAHA.109.900027","article-title":"Effect of Lipid lowering with rosuvastatin on progression of aortic valve stenosis: results of the aortic valve stenosis progression observation: measuring effects of rosuvastatin (ASTRONOMER) trial","volume":"121","author":"Chan","year":"2010","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2012.04.001_bb0120","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.jacc.2003.08.036","article-title":"Adverse outcome in aortic sclerosis is associated with coronary artery disease and inflammation","volume":"43","author":"Chandra","year":"2004","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pharmthera.2012.04.001_bb0125","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S0891-5849(03)00239-9","article-title":"Beyond LDL oxidation: ROS in vascular signal transduction","volume":"35","author":"Chen","year":"2003","journal-title":"Free Radic Biol Med"},{"key":"10.1016\/j.pharmthera.2012.04.001_bb0130","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/S0002-9149(02)02536-5","article-title":"Association of aortic valve stenosis with platelet hyperaggregability and impaired responsiveness to nitric oxide","volume":"90","author":"Chirkov","year":"2002","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.pharmthera.2012.04.001_bb0135","first-page":"28","article-title":"Loss of anti-aggregatory effects of aortic valve tissue in patients with aortic valve stenosis","volume":"15","author":"Chirkov","year":"2006","journal-title":"J Heart Valve Dis"},{"key":"10.1016\/j.pharmthera.2012.04.001_bb0140","doi-asserted-by":"crossref","first-page":"E19","DOI":"10.1016\/j.ahj.2003.10.017","article-title":"Safety and efficacy of angiotensin-converting enzyme inhibitors in symptomatic severe aortic valve stenosis: Symptomatic Cardiac Obstruction-Pilot Study of Enalapril in Aortic Valve Stenosis (SCOPE-AS)","volume":"147","author":"Chockalingam","year":"2004","journal-title":"Am Heart J"},{"key":"10.1016\/j.pharmthera.2012.04.001_bb0145","first-page":"365","article-title":"Development of aortic valve sclerosis in a rabbit model of atherosclerosis: an immunohistochemical and histological study","volume":"14","author":"Cimini","year":"2005","journal-title":"J Heart Valve Dis"},{"key":"10.1016\/j.pharmthera.2012.04.001_bb0150","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/S0735-1097(01)01746-6","article-title":"Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery: a report of the International Brachial Artery Reactivity Task Force","volume":"39","author":"Corretti","year":"2002","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pharmthera.2012.04.001_bb0155","doi-asserted-by":"crossref","first-page":"2345","DOI":"10.1001\/archinte.162.20.2345","article-title":"The risk of the development of aortic valve stenosis in patients with \u201cbenign\u201d aortic valve thickening","volume":"162","author":"Cosmi","year":"2002","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.pharmthera.2012.04.001_bb0160","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1093\/ageing\/afh175","article-title":"Calcific aortic valve stenosis: same old story?","volume":"33","author":"Cowell","year":"2004","journal-title":"Age Ageing"},{"key":"10.1016\/j.pharmthera.2012.04.001_bb0165","doi-asserted-by":"crossref","first-page":"2389","DOI":"10.1056\/NEJMoa043876","article-title":"A randomized trial of intensive lipid-lowering therapy in calcific aortic valve stenosis","volume":"352","author":"Cowell","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pharmthera.2012.04.001_bb0170","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1016\/j.jacc.2003.11.026","article-title":"Early experience with percutaneous transcatheter implantation of heart valve prosthesis for the treatment of end-stage inoperable patients with calcific aortic valve stenosis","volume":"43","author":"Cribier","year":"2004","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pharmthera.2012.04.001_bb0175","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/S0140-6736(86)90716-6","article-title":"Percutaneous transluminal valvuloplasty of acquired aortic valve stenosis in elderly patients: an alternative to valve replacement?","volume":"1","author":"Cribier","year":"1986","journal-title":"Lancet"},{"key":"10.1016\/j.pharmthera.2012.04.001_bb0180","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1006\/cbir.1995.1090","article-title":"Factors influencing myofibroblast differentiation during wound healing and fibrosis","volume":"19","author":"Desmouliere","year":"1995","journal-title":"Cell Biol Int"},{"key":"10.1016\/j.pharmthera.2012.04.001_bb0185","first-page":"134","article-title":"Myofibroblast differentiation during fibrosis","volume":"3","author":"Desmouliere","year":"1995","journal-title":"Exp Nephrol"},{"key":"10.1016\/j.pharmthera.2012.04.001_bb0190","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.4065\/83.9.1032","article-title":"Bisphosphonates: mechanism of action and role in clinical practice","volume":"83","author":"Drake","year":"2008","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.pharmthera.2012.04.001_bb0195","first-page":"875","article-title":"Profile and localization of matrix metalloproteinases (MMPs) and their tissue inhibitors (TIMPs) in human heart valves","volume":"11","author":"Dreger","year":"2002","journal-title":"J Heart Valve Dis"},{"key":"10.1016\/j.pharmthera.2012.04.001_bb0200","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1016\/j.jacc.2005.09.049","article-title":"A high fat\/high carbohydrate diet induces aortic valve disease in C57BL\/6J mice","volume":"47","author":"Drolet","year":"2006","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pharmthera.2012.04.001_bb0205","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1016\/j.jacc.2011.03.064","article-title":"Midwall fibrosis is an independent predictor of mortality in patients with aortic valve stenosis","volume":"58","author":"Dweck","year":"2011","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pharmthera.2012.04.001_bb0210","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/S1054-8807(00)00043-0","article-title":"Matrix metalloproteinase expression in nonrheumatic aortic valve stenosis","volume":"9","author":"Edep","year":"2000","journal-title":"Cardiovasc Pathol"},{"key":"10.1016\/j.pharmthera.2012.04.001_bb0215","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1016\/j.jacc.2008.11.056","article-title":"Endothelium-dependent regulation of the mechanical properties of aortic valve cusps","volume":"53","author":"El-Hamamsy","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pharmthera.2012.04.001_bb0220","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/S0002-9149(02)03011-4","article-title":"Progression of aortic valve sclerosis to aortic valve stenosis","volume":"91","author":"Faggiano","year":"2003","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.pharmthera.2012.04.001_bb0225","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1016\/S0002-8703(96)90440-8","article-title":"Progression of valvular aortic valve stenosis in adults: literature review and clinical implications","volume":"132","author":"Faggiano","year":"1996","journal-title":"Am Heart J"},{"key":"10.1016\/j.pharmthera.2012.04.001_bb0230","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1161\/01.RES.59.3.310","article-title":"Interstitial cells of the heart valves possess characteristics similar to smooth muscle cells","volume":"59","author":"Filip","year":"1986","journal-title":"Circ Res"},{"key":"10.1016\/j.pharmthera.2012.04.001_bb0235","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1093\/eurheartj\/ehi248","article-title":"Extracellular matrix remodelling in human aortic valve disease: the role of matrix metalloproteinases and their tissue inhibitors","volume":"26","author":"Fondard","year":"2005","journal-title":"Eur Heart J"},{"key":"10.1016\/j.pharmthera.2012.04.001_bb0240","doi-asserted-by":"crossref","first-page":"3316","DOI":"10.1161\/CIRCULATIONAHA.104.486738","article-title":"Spectrum of calcific aortic valve disease: pathogenesis, disease progression, and treatment strategies","volume":"111","author":"Freeman","year":"2005","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2012.04.001_bb0245","first-page":"281","article-title":"Surface structure of the human cardiac valve. A comparative study of normal and diseased valves","volume":"19","author":"Harasaki","year":"1978","journal-title":"J Cardiovasc Surg (Torino)"},{"key":"10.1016\/j.pharmthera.2012.04.001_bb0250","doi-asserted-by":"crossref","first-page":"e2","DOI":"10.1161\/CIRCRESAHA.107.156901","article-title":"Role of asymmetric dimethylarginine in vascular injury in transgenic mice overexpressing dimethylarginine dimethylaminohydrolase 2","volume":"101","author":"Hasegawa","year":"2007","journal-title":"Circ Res"},{"key":"10.1016\/j.pharmthera.2012.04.001_bb0255","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1093\/eurheartj\/ehm129","article-title":"Increased expression of profibrotic neutral endopeptidase and bradykinin type 1 receptors in stenotic aortic valves","volume":"28","author":"Helske","year":"2007","journal-title":"Eur Heart J"},{"key":"10.1016\/j.pharmthera.2012.04.001_bb0260","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1016\/j.jacc.2004.07.054","article-title":"Induction of local angiotensin II-producing systems in stenotic aortic valves","volume":"44","author":"Helske","year":"2004","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pharmthera.2012.04.001_bb0265","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.atherosclerosis.2007.03.040","article-title":"Complement system is activated in stenotic aortic valves","volume":"196","author":"Helske","year":"2008","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.pharmthera.2012.04.001_bb0270","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1093\/eurheartj\/ehi706","article-title":"Possible role for mast cell-derived cathepsin G in the adverse remodelling of stenotic aortic valves","volume":"27","author":"Helske","year":"2006","journal-title":"Eur Heart J"},{"key":"10.1016\/j.pharmthera.2012.04.001_bb0275","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1097\/HCO.0b013e328339f191","article-title":"Modulation of myocardial metabolism: an emerging therapeutic principle","volume":"25","author":"Horowitz","year":"2010","journal-title":"Curr Opin Cardiol"},{"key":"10.1016\/j.pharmthera.2012.04.001_bb0280","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.jchromb.2006.09.023","article-title":"An overview of plasma concentrations of asymmetric dimethylarginine (ADMA) in health and disease and in clinical studies: methodological considerations","volume":"851","author":"Horowitz","year":"2007","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"key":"10.1016\/j.pharmthera.2012.04.001_bb0285","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1111\/j.1752-8062.2009.00168.x","article-title":"Correlates of valvular ossification in patients with aortic valve stenosis","volume":"2","author":"Ing","year":"2009","journal-title":"Clin Transl Sci"},{"key":"10.1016\/j.pharmthera.2012.04.001_bb0290","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1540-8175.2010.01256.x","article-title":"Effect of bisphosphonates on the progression of degenerative aortic valve stenosis","volume":"28","author":"Innasimuthu","year":"2011","journal-title":"Echocardiography"},{"key":"10.1016\/j.pharmthera.2012.04.001_bb0295","doi-asserted-by":"crossref","first-page":"2714","DOI":"10.1093\/eurheartj\/ehi471","article-title":"Decision-making in elderly patients with severe aortic valve stenosis: why are so many denied surgery?","volume":"26","author":"Iung","year":"2005","journal-title":"Eur Heart J"},{"key":"10.1016\/j.pharmthera.2012.04.001_bb0300","doi-asserted-by":"crossref","first-page":"2533","DOI":"10.1161\/CIRCULATIONAHA.106.682450","article-title":"Association of fetuin-A with mitral annular calcification and aortic valve stenosis among persons with coronary heart disease: data from the Heart and Soul Study","volume":"115","author":"Ix","year":"2007","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2012.04.001_bb0305","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1097\/00005344-199503000-00018","article-title":"Direct evidence that perhexiline modifies myocardial substrate utilization from fatty acids to lactate","volume":"25","author":"Jeffrey","year":"1995","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1016\/j.pharmthera.2012.04.001_bb0310","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/S0002-9440(10)61698-7","article-title":"Matrix metalloproteinase-2 is associated with tenascin-C in calcific aortic valve stenosis","volume":"159","author":"Jian","year":"2001","journal-title":"Am J Pathol"},{"key":"10.1016\/j.pharmthera.2012.04.001_bb0315","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/S0003-4975(02)04312-6","article-title":"Progression of aortic valve stenosis: TGF-beta1 is present in calcified aortic valve cusps and promotes aortic valve interstitial cell calcification via apoptosis","volume":"75","author":"Jian","year":"2003","journal-title":"Ann Thorac Surg"},{"key":"10.1016\/j.pharmthera.2012.04.001_bb0320","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.yjmcc.2003.09.015","article-title":"Receptor activator of nuclear factor kappaB ligand and osteoprotegerin regulate aortic valve calcification","volume":"36","author":"Kaden","year":"2004","journal-title":"J Mol Cell Cardiol"},{"key":"10.1016\/j.pharmthera.2012.04.001_bb0325","first-page":"560","article-title":"Expression of bone sialoprotein and bone morphogenetic protein-2 in calcific aortic valve stenosis","volume":"13","author":"Kaden","year":"2004","journal-title":"J Heart Valve Dis"},{"key":"10.1016\/j.pharmthera.2012.04.001_bb0330","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.carpath.2005.01.002","article-title":"Inflammatory regulation of extracellular matrix remodeling in calcific aortic valve stenosis","volume":"14","author":"Kaden","year":"2005","journal-title":"Cardiovasc Pathol"},{"key":"10.1016\/j.pharmthera.2012.04.001_bb0335","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/S0021-9150(03)00284-3","article-title":"Interleukin-1 beta promotes matrix metalloproteinase expression and cell proliferation in calcific aortic valve stenosis","volume":"170","author":"Kaden","year":"2003","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.pharmthera.2012.04.001_bb0340","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.yexmp.2004.09.001","article-title":"Influence of receptor activator of nuclear factor kappa B on human aortic valve myofibroblasts","volume":"78","author":"Kaden","year":"2005","journal-title":"Exp Mol Pathol"},{"key":"10.1016\/j.pharmthera.2012.04.001_bb0345","first-page":"193","article-title":"Systemic and local levels of fetuin-A in calcific aortic valve stenosis","volume":"20","author":"Kaden","year":"2007","journal-title":"Int J Mol Med"},{"key":"10.1016\/j.pharmthera.2012.04.001_bb0350","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.ejphar.2005.11.058","article-title":"Effect of the anti-anginal agent, perhexiline, on neutrophil, valvular and vascular superoxide formation","volume":"531","author":"Kennedy","year":"2006","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.pharmthera.2012.04.001_bb0355","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.ejphar.2008.11.029","article-title":"Inhibition of calcifying nodule formation in cultured porcine aortic valve cells by nitric oxide donors","volume":"602","author":"Kennedy","year":"2009","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.pharmthera.2012.04.001_bb0360","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1056\/NEJMoa022021","article-title":"Nitroprusside in critically ill patients with left ventricular dysfunction and aortic valve stenosis","volume":"348","author":"Khot","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pharmthera.2012.04.001_bb0365","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/S0003-4975(10)62112-1","article-title":"The association of unexplained gastrointestinal bleeding with calcific aortic valve stenosis","volume":"44","author":"King","year":"1987","journal-title":"Ann Thorac Surg"},{"key":"10.1016\/j.pharmthera.2012.04.001_bb0370","doi-asserted-by":"crossref","first-page":"2054","DOI":"10.1093\/eurheartj\/ehp158","article-title":"Association of fetuin-A levels with the progression of aortic valve calcification in non-dialyzed patients","volume":"30","author":"Koos","year":"2009","journal-title":"Eur Heart J"},{"key":"10.1016\/j.pharmthera.2012.04.001_bb0375","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1160\/TH08-09-0611","article-title":"Relation of circulating Matrix Gla-Protein and anticoagulation status in patients with aortic valve calcification","volume":"101","author":"Koos","year":"2009","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.pharmthera.2012.04.001_bb0380","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1097\/00005344-199008000-00006","article-title":"Release of endothelium-derived relaxing factors from canine cardiac valves","volume":"16","author":"Ku","year":"1990","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1016\/j.pharmthera.2012.04.001_bb0385","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/S0735-1097(99)00584-7","article-title":"Observed and relative survival after aortic valve replacement","volume":"35","author":"Kvidal","year":"2000","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pharmthera.2012.04.001_bb0390","doi-asserted-by":"crossref","first-page":"3280","DOI":"10.1161\/CIRCULATIONAHA.105.551457","article-title":"Metabolic modulation with perhexiline in chronic heart failure: a randomized, controlled trial of short-term use of a novel treatment","volume":"112","author":"Lee","year":"2005","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2012.04.001_bb0395","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1161\/ATVBAHA.107.156745","article-title":"Oxidant generation predominates around calcifying foci and enhances progression of aortic valve calcification","volume":"28","author":"Liberman","year":"2008","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.pharmthera.2012.04.001_bb0400","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.ejphar.2007.01.001","article-title":"Effects of perhexiline and nitroglycerin on vascular, neutrophil and platelet function in patients with stable angina pectoris","volume":"560","author":"Liberts","year":"2007","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.pharmthera.2012.04.001_bb0405","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1002\/jcp.21861","article-title":"Hypoxia-induced expression of bradykinin type-2 receptors in endothelial cells triggers NO production, cell migration, and angiogenesis","volume":"221","author":"Liesmaa","year":"2009","journal-title":"J Cell Physiol"},{"key":"10.1016\/j.pharmthera.2012.04.001_bb0410","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1016\/0735-1097(93)90249-Z","article-title":"Prevalence of aortic valve abnormalities in the elderly: an echocardiographic study of a random population sample","volume":"21","author":"Lindroos","year":"1993","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pharmthera.2012.04.001_bb0415","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1253\/circj.72.245","article-title":"Parathyroid hormone and vitamin D levels are independently associated with calcific aortic valve stenosis","volume":"72","author":"Linhartova","year":"2008","journal-title":"Circ J"},{"key":"10.1016\/j.pharmthera.2012.04.001_bb0420","doi-asserted-by":"crossref","first-page":"6269","DOI":"10.1182\/blood-2011-08-335612","article-title":"Warfarin and acetaminophen interaction: a summary of the evidence and biological plausibility","volume":"118","author":"Lopes","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.pharmthera.2012.04.001_bb0425","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1016\/S0140-6736(87)91370-5","article-title":"Aortic and mitral valve calcification in patients with end-stage renal disease","volume":"2","author":"Maher","year":"1987","journal-title":"Lancet"},{"key":"10.1016\/j.pharmthera.2012.04.001_bb0430","first-page":"1595","article-title":"Incidence and development of aortic valve stenosis in chronic hemodialysis. An ultrasonographic and biological study of 112 patients","volume":"90","author":"Malergue","year":"1997","journal-title":"Arch Mal Coeur Vaiss"},{"key":"10.1016\/j.pharmthera.2012.04.001_bb0435","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1083\/jcb.139.6.1477","article-title":"Sarcomeric gene expression and contractility in myofibroblasts","volume":"139","author":"Mayer","year":"1997","journal-title":"J Cell Biol"},{"key":"10.1016\/j.pharmthera.2012.04.001_bb0440","doi-asserted-by":"crossref","first-page":"C29","DOI":"10.1152\/ajpcell.00137.2007","article-title":"Expression of functional Toll-like receptors 2 and 4 in human aortic valve interstitial cells: potential roles in aortic valve inflammation and stenosis","volume":"294","author":"Meng","year":"2008","journal-title":"Am J Physiol Cell Physiol"},{"key":"10.1016\/j.pharmthera.2012.04.001_bb0445","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1161\/01.ATV.0000255952.47980.c2","article-title":"Aortic valve calcification: determinants and progression in the population","volume":"27","author":"Messika-Zeitoun","year":"2007","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.pharmthera.2012.04.001_bb0450","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/j.jacc.2008.05.043","article-title":"Dysregulation of antioxidant mechanisms contributes to increased oxidative stress in calcific aortic valvular stenosis in humans","volume":"52","author":"Miller","year":"2008","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pharmthera.2012.04.001_bb0455","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1016\/j.amjcard.2004.08.013","article-title":"Mechanisms of aortic valve calcification","volume":"94","author":"Mohler Iii","year":"2004","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.pharmthera.2012.04.001_bb0460","first-page":"254","article-title":"Identification and characterization of calcifying valve cells from human and canine aortic valves","volume":"8","author":"Mohler","year":"1999","journal-title":"J Heart Valve Dis"},{"key":"10.1016\/j.pharmthera.2012.04.001_bb0465","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1161\/01.CIR.103.11.1522","article-title":"Bone formation and inflammation in cardiac valves","volume":"103","author":"Mohler","year":"2001","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2012.04.001_bb0470","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1161\/ATVBAHA.107.154989","article-title":"Association between plasma LDL particle size, valvular accumulation of oxidized LDL, and inflammation in patients with aortic valve stenosis","volume":"28","author":"Mohty","year":"2008","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.pharmthera.2012.04.001_bb0475","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1016\/j.jacc.2006.07.072","article-title":"Rosuvastatin affecting aortic valve endothelium to slow the progression of aortic valve stenosis","volume":"49","author":"Moura","year":"2007","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pharmthera.2012.04.001_bb0480","first-page":"231","article-title":"Cell biology of valvular interstitial cells","volume":"12","author":"Mulholland","year":"1996","journal-title":"Can J Cardiol"},{"issue":"807\u2013809","key":"10.1016\/j.pharmthera.2012.04.001_bb0485","first-page":"A809","article-title":"Rate of progression of valvular aortic valve stenosis in patients > or = 60 years of age","volume":"87","author":"Nassimiha","year":"2001","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.pharmthera.2012.04.001_bb0490","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.niox.2006.10.003","article-title":"Aortic valve stenosis is associated with elevated plasma levels of asymmetric dimethylarginine (ADMA)","volume":"16","author":"Ngo","year":"2007","journal-title":"Nitric Oxide"},{"key":"10.1016\/j.pharmthera.2012.04.001_bb0495","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/j.ejphar.2008.05.051","article-title":"Vitamin D(2) supplementation induces the development of aortic valve stenosis in rabbits: interactions with endothelial function and thioredoxin-interacting protein","volume":"590","author":"Ngo","year":"2008","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.pharmthera.2012.04.001_bb0500","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1111\/j.1476-5381.2010.01084.x","article-title":"Ramipril retards development of aortic valve stenosis in a rabbit model: mechanistic considerations","volume":"162","author":"Ngo","year":"2011","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.pharmthera.2012.04.001_bb0505","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/j.jcmg.2009.03.016","article-title":"Determinants of occurrence of aortic sclerosis in an aging population","volume":"2","author":"Ngo","year":"2009","journal-title":"JACC Cardiovasc Imaging"},{"key":"10.1016\/j.pharmthera.2012.04.001_bb0510","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1161\/hc3601.094304","article-title":"Significance of chymase-dependent angiotensin II-forming pathway in the development of vascular proliferation","volume":"104","author":"Nishimoto","year":"2001","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2012.04.001_bb0515","doi-asserted-by":"crossref","first-page":"1992","DOI":"10.1016\/j.jacc.2007.07.064","article-title":"Clinical factors, but not C-reactive protein, predict progression of calcific aortic-valve disease: the Cardiovascular Health Study","volume":"50","author":"Novaro","year":"2007","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pharmthera.2012.04.001_bb0520","doi-asserted-by":"crossref","first-page":"2205","DOI":"10.1161\/hc4301.098249","article-title":"Effect of hydroxymethylglutaryl coenzyme a reductase inhibitors on the progression of calcific aortic valve stenosis","volume":"104","author":"Novaro","year":"2001","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2012.04.001_bb0525","doi-asserted-by":"crossref","first-page":"2163","DOI":"10.1161\/01.CIR.92.8.2163","article-title":"Osteopontin is expressed in human aortic valvular lesions","volume":"92","author":"O'Brien","year":"1995","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2012.04.001_bb0530","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1001\/archinte.165.8.858","article-title":"Angiotensin-converting enzyme inhibitors and change in aortic valve calcium","volume":"165","author":"O'Brien","year":"2005","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.pharmthera.2012.04.001_bb0535","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1161\/01.ATV.16.4.523","article-title":"Apolipoproteins B, (a), and E accumulate in the morphologically early lesion of \u2018degenerative\u2019 valvular aortic valve stenosis","volume":"16","author":"O'Brien","year":"1996","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.pharmthera.2012.04.001_bb0540","doi-asserted-by":"crossref","first-page":"2224","DOI":"10.1161\/01.CIR.0000035655.45453.D2","article-title":"Association of angiotensin-converting enzyme with low-density lipoprotein in aortic valvular lesions and in human plasma","volume":"106","author":"O'Brien","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2012.04.001_bb0545","doi-asserted-by":"crossref","first-page":"185","DOI":"10.2310\/6650.2004.03025","article-title":"Hemodynamic effects of the angiotensin-converting enzyme inhibitor, ramipril, in patients with mild to moderate aortic valve stenosis and preserved left ventricular function","volume":"52","author":"O'Brien","year":"2004","journal-title":"J Investig Med"},{"key":"10.1016\/j.pharmthera.2012.04.001_bb0550","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.amjcard.2004.08.080","article-title":"Aortic valve sclerosis relates to cardiovascular events in patients with hypertension (a LIFE substudy)","volume":"95","author":"Olsen","year":"2005","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.pharmthera.2012.04.001_bb0555","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1016\/0735-1097(94)90606-8","article-title":"Accumulation of T lymphocytes and expression of interleukin-2 receptors in nonrheumatic stenotic aortic valves","volume":"23","author":"Olsson","year":"1994","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pharmthera.2012.04.001_bb0560","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1161\/01.ATV.19.5.1218","article-title":"Presence of oxidized low density lipoprotein in nonrheumatic stenotic aortic valves","volume":"19","author":"Olsson","year":"1999","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.pharmthera.2012.04.001_bb0565","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1136\/heart.85.6.635","article-title":"The vitamin D receptor genotype predisposes to the development of calcific aortic valve stenosis","volume":"85","author":"Ortlepp","year":"2001","journal-title":"Heart"},{"key":"10.1016\/j.pharmthera.2012.04.001_bb0570","first-page":"502","article-title":"Lower serum calcium levels are associated with greater calcium hydroxyapatite deposition in native aortic valves of male patients with severe calcific aortic valve stenosis","volume":"15","author":"Ortlepp","year":"2006","journal-title":"J Heart Valve Dis"},{"key":"10.1016\/j.pharmthera.2012.04.001_bb0575","doi-asserted-by":"crossref","first-page":"I566","DOI":"10.1161\/CIRCULATIONAHA.105.001214","article-title":"A novel role of extracellular nucleotides in valve calcification: a potential target for atorvastatin","volume":"114","author":"Osman","year":"2006","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2012.04.001_bb0580","doi-asserted-by":"crossref","first-page":"I547","DOI":"10.1161\/CIRCULATIONAHA.105.001115","article-title":"Role of human valve interstitial cells in valve calcification and their response to atorvastatin","volume":"114","author":"Osman","year":"2006","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2012.04.001_bb0585","doi-asserted-by":"crossref","first-page":"2262","DOI":"10.1161\/01.CIR.95.9.2262","article-title":"Prospective study of asymptomatic valvular aortic valve stenosis. Clinical, echocardiographic, and exercise predictors of outcome","volume":"95","author":"Otto","year":"1997","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2012.04.001_bb0590","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1161\/01.CIR.90.2.844","article-title":"Characterization of the early lesion of \u2018degenerative\u2019 valvular aortic valve stenosis. Histological and immunohistochemical studies","volume":"90","author":"Otto","year":"1994","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2012.04.001_bb0595","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1056\/NEJM199907153410302","article-title":"Association of aortic-valve sclerosis with cardiovascular mortality and morbidity in the elderly","volume":"341","author":"Otto","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pharmthera.2012.04.001_bb0600","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1136\/heart.85.6.601","article-title":"Why is there discordance between calcific aortic valve stenosis and coronary artery disease?","volume":"85","author":"Otto","year":"2001","journal-title":"Heart"},{"key":"10.1016\/j.pharmthera.2012.04.001_bb0605","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1016\/j.jcmg.2009.02.016","article-title":"Is it time for a new paradigm in calcific aortic valve disease?","volume":"2","author":"Owens","year":"2009","journal-title":"JACC Cardiovasc Imaging"},{"key":"10.1016\/j.pharmthera.2012.04.001_bb0610","doi-asserted-by":"crossref","first-page":"2116","DOI":"10.1016\/j.athoracsur.2006.07.043","article-title":"Malignant natural history of asymptomatic severe aortic valve stenosis: benefit of aortic valve replacement","volume":"82","author":"Pai","year":"2006","journal-title":"Ann Thorac Surg"},{"key":"10.1016\/j.pharmthera.2012.04.001_bb0615","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1161\/01.CIR.101.21.2497","article-title":"New insights into the progression of aortic valve stenosis: implications for secondary prevention","volume":"101","author":"Palta","year":"2000","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2012.04.001_bb0620","doi-asserted-by":"crossref","first-page":"805","DOI":"10.2353\/ajpath.2007.061243","article-title":"Thioredoxins, mitochondria, and hypertension","volume":"170","author":"Patwari","year":"2007","journal-title":"Am J Pathol"},{"key":"10.1016\/j.pharmthera.2012.04.001_bb0625","doi-asserted-by":"crossref","first-page":"c40","DOI":"10.1159\/000071280","article-title":"Accelerated progression of calcific aortic valve stenosis in dialysis patients","volume":"94","author":"Perkovic","year":"2003","journal-title":"Nephron Clin Pract"},{"key":"10.1016\/j.pharmthera.2012.04.001_bb0630","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1093\/eurjhf\/hfp106","article-title":"Multi-centre experience on the use of perhexiline in chronic heart failure and refractory angina: old drug, new hope","volume":"11","author":"Phan","year":"2009","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.pharmthera.2012.04.001_bb0635","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1161\/01.CIR.0000091405.00772.6E","article-title":"Effects of eplerenone, enalapril, and eplerenone\/enalapril in patients with essential hypertension and left ventricular hypertrophy: the 4E-left ventricular hypertrophy study","volume":"108","author":"Pitt","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2012.04.001_bb0640","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1056\/NEJMoa030207","article-title":"Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction","volume":"348","author":"Pitt","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pharmthera.2012.04.001_bb0645","doi-asserted-by":"crossref","first-page":"7317","DOI":"10.1074\/jbc.M412817200","article-title":"Bisphosphonates and estrogens inhibit osteocyte apoptosis via distinct molecular mechanisms downstream of extracellular signal-regulated kinase activation","volume":"280","author":"Plotkin","year":"2005","journal-title":"J Biol Chem"},{"key":"10.1016\/j.pharmthera.2012.04.001_bb0650","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1172\/JCI6800","article-title":"Prevention of osteocyte and osteoblast apoptosis by bisphosphonates and calcitonin","volume":"104","author":"Plotkin","year":"1999","journal-title":"J Clin Invest"},{"key":"10.1016\/j.pharmthera.2012.04.001_bb0655","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/S0735-1097(02)02622-0","article-title":"Aortic valve sclerosis is associated with systemic endothelial dysfunction","volume":"41","author":"Poggianti","year":"2003","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pharmthera.2012.04.001_bb0660","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1016\/S0003-4975(98)00075-7","article-title":"Endothelial-dependent dynamic and antithrombotic properties of porcine aortic and pulmonary valves","volume":"65","author":"Pompilio","year":"1998","journal-title":"Ann Thorac Surg"},{"key":"10.1016\/j.pharmthera.2012.04.001_bb0665","doi-asserted-by":"crossref","first-page":"C1","DOI":"10.1111\/j.1469-7793.1999.001af.x","article-title":"Myofibroblasts. I. Paracrine cells important in health and disease","volume":"277","author":"Powell","year":"1999","journal-title":"Am J Physiol"},{"key":"10.1016\/j.pharmthera.2012.04.001_bb0670","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1161\/ATVBAHA.107.156752","article-title":"Calcific aortic valve stenosis: lessons learned from experimental and clinical studies","volume":"29","author":"Rajamannan","year":"2009","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.pharmthera.2012.04.001_bb0675","first-page":"371","article-title":"Experimental hypercholesterolemia induces apoptosis in the aortic valve","volume":"10","author":"Rajamannan","year":"2001","journal-title":"J Heart Valve Dis"},{"key":"10.1016\/j.pharmthera.2012.04.001_bb0680","doi-asserted-by":"crossref","first-page":"I229","DOI":"10.1161\/01.CIRCULATIONAHA.104.524306","article-title":"Atorvastatin inhibits hypercholesterolemia-induced calcification in the aortic valves via the Lrp5 receptor pathway","volume":"112","author":"Rajamannan","year":"2005","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2012.04.001_bb0685","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1083\/jcb.200303194","article-title":"Skeletal myosin heavy chain function in cultured lung myofibroblasts","volume":"163","author":"Rice","year":"2003","journal-title":"J Cell Biol"},{"key":"10.1016\/j.pharmthera.2012.04.001_bb0690","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1161\/01.CIR.61.3.496","article-title":"Surface topography of stenotic aortic valves by scanning electron microscopy","volume":"61","author":"Riddle","year":"1980","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2012.04.001_bb0695","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1016\/S0735-1097(83)80039-4","article-title":"Evaluation of platelet reactivity in patients with valvular heart disease","volume":"1","author":"Riddle","year":"1983","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pharmthera.2012.04.001_bb0700","doi-asserted-by":"crossref","first-page":"H1802","DOI":"10.1152\/ajpheart.01096.2001","article-title":"Aldosterone induces a vascular inflammatory phenotype in the rat heart","volume":"283","author":"Rocha","year":"2002","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"10.1016\/j.pharmthera.2012.04.001_bb0705","doi-asserted-by":"crossref","first-page":"2692","DOI":"10.1172\/JCI118722","article-title":"Bisphosphonates: mechanisms of action","volume":"97","author":"Rodan","year":"1996","journal-title":"J Clin Invest"},{"key":"10.1016\/j.pharmthera.2012.04.001_bb0710","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1056\/NEJM200008313430903","article-title":"Predictors of outcome in severe, asymptomatic aortic valve stenosis","volume":"343","author":"Rosenhek","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pharmthera.2012.04.001_bb0715","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1161\/01.CIR.0000140723.15274.53","article-title":"Statins but not angiotensin-converting enzyme inhibitors delay progression of aortic valve stenosis","volume":"110","author":"Rosenhek","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2012.04.001_bb0720","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1161\/01.CIR.38.1S5.V-61","article-title":"Aortic valve stenosis","volume":"38","author":"Ross","year":"1968","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2012.04.001_bb0725","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1056\/NEJMoa0804602","article-title":"Intensive lipid lowering with simvastatin and ezetimibe in aortic valve stenosis","volume":"359","author":"Rossebo","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pharmthera.2012.04.001_bb0730","first-page":"144","article-title":"Differentiation repertoire of fibroblastic cells: expression of cytoskeletal proteins as marker of phenotypic modulations","volume":"63","author":"Sappino","year":"1990","journal-title":"Lab Invest"},{"key":"10.1016\/j.pharmthera.2012.04.001_bb0735","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/S0735-1097(01)01705-3","article-title":"Progression of human aortic valve stenosis is associated with tenascin-C expression","volume":"39","author":"Satta","year":"2002","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pharmthera.2012.04.001_bb0740","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/S0003-4975(03)00529-0","article-title":"Evidence for an altered balance between matrix metalloproteinase-9 and its inhibitors in calcific aortic valve stenosis","volume":"76","author":"Satta","year":"2003","journal-title":"Ann Thorac Surg"},{"key":"10.1016\/j.pharmthera.2012.04.001_bb0745","first-page":"262","article-title":"Parathyroid hormone gene variant and calcific aortic valve stenosis","volume":"18","author":"Schmitz","year":"2009","journal-title":"J Heart Valve Dis"},{"key":"10.1016\/j.pharmthera.2012.04.001_bb0750","first-page":"1","article-title":"Aortic valve structure\u2013function correlations: role of elastic fibers no longer a stretch of the imagination","volume":"6","author":"Schoen","year":"1997","journal-title":"J Heart Valve Dis"},{"key":"10.1016\/j.pharmthera.2012.04.001_bb0755","doi-asserted-by":"crossref","first-page":"2666","DOI":"10.1161\/01.ATV.0000248914.21018.f1","article-title":"Nitric oxide-dependent suppression of thioredoxin-interacting protein expression enhances thioredoxin activity","volume":"26","author":"Schulze","year":"2006","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.pharmthera.2012.04.001_bb0760","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1160\/TH08-02-0087","article-title":"Matrix Gla-protein: the calcification inhibitor in need of vitamin K","volume":"100","author":"Schurgers","year":"2008","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.pharmthera.2012.04.001_bb0765","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1038\/nrneph.2011.31","article-title":"The role of asymmetric and symmetric dimethylarginines in renal disease","volume":"7","author":"Schwedhelm","year":"2011","journal-title":"Nat Rev Nephrol"},{"key":"10.1016\/j.pharmthera.2012.04.001_bb0770","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.vph.2009.11.010","article-title":"Mechanisms of nitric oxide synthase uncoupling in endotoxin-induced acute lung injury: role of asymmetric dimethylarginine","volume":"52","author":"Sharma","year":"2010","journal-title":"Vascul Pharmacol"},{"key":"10.1016\/j.pharmthera.2012.04.001_bb0775","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1016\/S0140-6736(02)08161-8","article-title":"HMG CoA reductase inhibitor (statin) and aortic valve calcium","volume":"359","author":"Shavelle","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.pharmthera.2012.04.001_bb0780","doi-asserted-by":"crossref","first-page":"2789","DOI":"10.1016\/j.jacc.2009.12.068","article-title":"Bicuspid aortic valve disease","volume":"55","author":"Siu","year":"2010","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pharmthera.2012.04.001_bb0785","first-page":"275","article-title":"Myofibroblasts from diverse pathologic settings are heterogeneous in their content of actin isoforms and intermediate filament proteins","volume":"60","author":"Skalli","year":"1989","journal-title":"Lab Invest"},{"key":"10.1016\/j.pharmthera.2012.04.001_bb0790","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.amjcard.2009.02.051","article-title":"Osteoporosis treatment and progression of aortic valve stenosis","volume":"104","author":"Skolnick","year":"2009","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.pharmthera.2012.04.001_bb0795","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1136\/hrt.2005.069815","article-title":"Tissue resident C reactive protein in degenerative aortic valves: correlation with serum C reactive protein concentrations and modification by statins","volume":"92","author":"Skowasch","year":"2006","journal-title":"Heart"},{"key":"10.1016\/j.pharmthera.2012.04.001_bb0800","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1002\/path.850","article-title":"Expression of MMP2, MMP9, MT1-MMP, TIMP1, and TIMP2 mRNA in valvular lesions of the heart","volume":"194","author":"Soini","year":"2001","journal-title":"J Pathol"},{"key":"10.1016\/j.pharmthera.2012.04.001_bb0805","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/S0002-9149(77)80185-9","article-title":"Continuing disease process of calcific aortic valve stenosis. Role of microthrombi and turbulent flow","volume":"39","author":"Stein","year":"1977","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.pharmthera.2012.04.001_bb0810","first-page":"187","article-title":"Differential profile of the OPG\/RANKL\/RANK-system in degenerative aortic native and bioprosthetic valves","volume":"17","author":"Steinmetz","year":"2008","journal-title":"J Heart Valve Dis"},{"key":"10.1016\/j.pharmthera.2012.04.001_bb0815","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1016\/j.ahj.2008.03.012","article-title":"A randomized trial of the aldosterone-receptor antagonist eplerenone in asymptomatic moderate\u2013severe aortic valve stenosis","volume":"156","author":"Stewart","year":"2008","journal-title":"Am Heart J"},{"key":"10.1016\/j.pharmthera.2012.04.001_bb0820","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1016\/S0735-1097(96)00563-3","article-title":"Clinical factors associated with calcific aortic valve disease. Cardiovascular Health Study","volume":"29","author":"Stewart","year":"1997","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pharmthera.2012.04.001_bb0825","doi-asserted-by":"crossref","first-page":"1682","DOI":"10.1161\/01.ATV.0000136656.26019.6e","article-title":"Asymmetric dimethylarginine produces vascular lesions in endothelial nitric oxide synthase-deficient mice: involvement of renin\u2013angiotensin system and oxidative stress","volume":"24","author":"Suda","year":"2004","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.pharmthera.2012.04.001_bb0830","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/S0008-6363(02)00617-X","article-title":"ADMA and oxidative stress are responsible for endothelial dysfunction in hyperhomocyst(e)inemia: effects of L-arginine and B vitamins","volume":"57","author":"Sydow","year":"2003","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.pharmthera.2012.04.001_bb0835","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.ejphar.2006.12.006","article-title":"Prevention of aortic calcification by etidronate in the renal failure rat model","volume":"558","author":"Tamura","year":"2007","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.pharmthera.2012.04.001_bb0840","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.jacc.2005.03.058","article-title":"Age-associated aortic valve stenosis in apolipoprotein E-deficient mice","volume":"46","author":"Tanaka","year":"2005","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pharmthera.2012.04.001_bb0845","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1093\/oxfordjournals.eurheartj.a062307","article-title":"Spontaneous course of aortic valve disease","volume":"8","author":"Turina","year":"1987","journal-title":"Eur Heart J"},{"key":"10.1016\/j.pharmthera.2012.04.001_bb0850","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1111\/j.1365-2796.2010.02264.x","article-title":"Undercarboxylated matrix Gla protein is associated with indices of heart failure and mortality in symptomatic aortic valve stenosis","volume":"268","author":"Ueland","year":"2010","journal-title":"J Intern Med"},{"key":"10.1016\/j.pharmthera.2012.04.001_bb0855","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1111\/j.1445-5994.1997.tb00909.x","article-title":"Perhexiline improves symptomatic status in elderly patients with severe aortic valve stenosis","volume":"27","author":"Unger","year":"1997","journal-title":"Aust N Z J Med"},{"key":"10.1016\/j.pharmthera.2012.04.001_bb0860","first-page":"217","article-title":"Evolutive aortic valve stenosis in hemodialysis patients: analysis of risk factors","volume":"20","author":"Urena","year":"1999","journal-title":"Nephrologie"},{"key":"10.1016\/j.pharmthera.2012.04.001_bb0865","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1093\/eurheartj\/ehr491","article-title":"Transcatheter aortic valve implantation: 3-year outcomes of self-expanding CoreValve prosthesis","volume":"33","author":"Ussia","year":"2012","journal-title":"Eur Heart J"},{"key":"10.1016\/j.pharmthera.2012.04.001_bb0870","doi-asserted-by":"crossref","first-page":"2111","DOI":"10.1016\/j.athoracsur.2006.07.048","article-title":"Clinical profile and natural history of 453 nonsurgically managed patients with severe aortic valve stenosis","volume":"82","author":"Varadarajan","year":"2006","journal-title":"Ann Thorac Surg"},{"key":"10.1016\/j.pharmthera.2012.04.001_bb0875","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1161\/HYPERTENSIONAHA.108.116731","article-title":"ADMA impairs nitric oxide-mediated arteriolar function due to increased superoxide production by angiotensin II-NAD(P)H oxidase pathway","volume":"52","author":"Veresh","year":"2008","journal-title":"Hypertension"},{"key":"10.1016\/j.pharmthera.2012.04.001_bb0880","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1053\/gast.2001.21204","article-title":"Abnormal von Willebrand factor in bleeding angiodysplasias of the digestive tract","volume":"120","author":"Veyradier","year":"2001","journal-title":"Gastroenterology"},{"key":"10.1016\/j.pharmthera.2012.04.001_bb0885","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1056\/NEJMoa022831","article-title":"Acquired von Willebrand syndrome in aortic valve stenosis","volume":"349","author":"Vincentelli","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pharmthera.2012.04.001_bb0890","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1016\/j.atherosclerosis.2009.10.030","article-title":"Heart valve sclerosis predicts all-cause and cardiovascular mortality","volume":"209","author":"Volzke","year":"2010","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.pharmthera.2012.04.001_bb0895","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1136\/heart.88.4.348","article-title":"T lymphocyte infiltration in non-rheumatic aortic valve stenosis: a comparative descriptive study between tricuspid and bicuspid aortic valves","volume":"88","author":"Wallby","year":"2002","journal-title":"Heart"},{"key":"10.1016\/j.pharmthera.2012.04.001_bb0900","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/0140-6736(92)92434-H","article-title":"Aortic valve stenosis and bleeding gastrointestinal angiodysplasia: is acquired von Willebrand's disease the link?","volume":"340","author":"Warkentin","year":"1992","journal-title":"Lancet"},{"key":"10.1016\/j.pharmthera.2012.04.001_bb0905","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1080\/00313029700169315","article-title":"Calcification of the aortic valve: its progression and grading","volume":"29","author":"Warren","year":"1997","journal-title":"Pathology"},{"key":"10.1016\/j.pharmthera.2012.04.001_bb0910","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1161\/CIRCULATIONAHA.106.634139","article-title":"Calcific aortic valve stenosis in old hypercholesterolemic mice","volume":"114","author":"Weiss","year":"2006","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2012.04.001_bb0915","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1053\/euhj.2002.3296","article-title":"Beneficial clinical effects of perhexiline in patients with stable angina pectoris and acute coronary syndromes are associated with potentiation of platelet responsiveness to nitric oxide","volume":"23","author":"Willoughby","year":"2002","journal-title":"Eur Heart J"},{"key":"10.1016\/j.pharmthera.2012.04.001_bb0920","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/S0002-9149(01)02241-X","article-title":"Determinants of progression of aortic valve stenosis in patients aged > or = 40 years","volume":"89","author":"Wongpraparut","year":"2002","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.pharmthera.2012.04.001_bb0925","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/hr.2009.225","article-title":"Prognostic factors for progression of early- and late-stage calcific aortic valve disease in Japanese: the Japanese Aortic Valve Stenosis Study (JASS) Retrospective Analysis","volume":"33","author":"Yamamoto","year":"2010","journal-title":"Hypertens Res"},{"key":"10.1016\/j.pharmthera.2012.04.001_bb0930","first-page":"264","article-title":"Bicuspid aortic valve","volume":"8","author":"Yener","year":"2002","journal-title":"Ann Thorac Cardiovasc Surg"},{"key":"10.1016\/j.pharmthera.2012.04.001_bb0935","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1161\/ATVBAHA.108.182394","article-title":"Calcification by valve interstitial cells is regulated by the stiffness of the extracellular matrix","volume":"29","author":"Yip","year":"2009","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.pharmthera.2012.04.001_bb0940","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1124\/jpet.110.177915","article-title":"Tumor necrosis factor-alpha accelerates the calcification of human aortic valve interstitial cells obtained from patients with calcific aortic valve stenosis via the BMP2\u2013Dlx5 pathway","volume":"337","author":"Yu","year":"2011","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.pharmthera.2012.04.001_bb0945","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1038\/ni.1831","article-title":"Thioredoxin-interacting protein links oxidative stress to inflammasome activation","volume":"11","author":"Zhou","year":"2010","journal-title":"Nat Immunol"}],"container-title":["Pharmacology & Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163725812000678?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163725812000678?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,1,12]],"date-time":"2022-01-12T10:54:13Z","timestamp":1641984853000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0163725812000678"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,7]]},"references-count":189,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2012,7]]}},"alternative-id":["S0163725812000678"],"URL":"https:\/\/doi.org\/10.1016\/j.pharmthera.2012.04.001","relation":{},"ISSN":["0163-7258"],"issn-type":[{"value":"0163-7258","type":"print"}],"subject":[],"published":{"date-parts":[[2012,7]]}}}